MDCO News and Press, The Medicines Company From 11/25/19

News Items That are Positive for Markets Ironically, two interesting items come from Bloomberg Media, and then additional news that Mike Bloomberg is running is cheering the market. Firstly, items out of China; "China said it will raise penalties on violations of intellectual property rig...

JanOne (NASDAQ: JAN ) +127%  on acquiring worldwide license for treatment of Peripheral Arterial Disease. More news on: JanOne Inc., Sorrento Therapeutics, Inc., The Medicines Company, Stocks on the move, Read more ...

It took two solid decades for  Alnylam   (NASDAQ: ALNY)  to carry its first new drug candidate across the finish line, but investors didn't need to wait long for the next one. The FDA approved the company's second drug just 16 months later, and the pace will probably accelerate.&#...

Merger activity decreased, with three new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Carolina Financial Corporation (CARO) by United Bankshares (UBSI) for $1.1 billion in an all-stock deal. Under the terms of the agreement, United will...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Marking the biggest ever deal in the luxury sector, LVMH (LVMHF) is buying Tiffany & Company (TIF) for $16.2B, adding an icon...

- The Medicines Company to be acquired by Novartis AG for $85 per share in cash, representing 45% premium to its unaffected share price and a 57% premium to its unaffected one-week average price - Inclisiran, The Medicines Company’s investigational, innovative, potent twice-annual ...

Continuing to build up its heart treatment portfolio, Novartis (NYSE: NVS ) is nearing a deal to buy cholesterol-drug maker The Medicines Co. (NASDAQ: MDCO ) for $85 a share, or nearly $7B, WSJ reports . More news on: Novartis AG, The Medicines Company, Ionis Pharmaceuticals, Inc., Heal...

It's been a long road for RNA interference (RNAi): From a Nobel prize and overpriced deals more than a decade ago, to the Food and Drug Administration approval of the second RNAi drug this week. Alnylam Pharmaceuticals (NASDAQ: ALNY) got its first RNAi drug, Onpattro, approved for trans...

Healthcare Pulse Healthcare is at its all-time highs eclipsing the highs recorded a year earlier during the Oct-Nov 2018 period. Of course, if one looks at the broader market which has been recording such all-time highs since the summer of this year, it's understandable to shrug shoulders ...

With Alnylam Pharmaceuticals ( ALNY ) shares up almost 30% since my last update on the company, I can’t complain that the Street is undervaluing this RNAi pioneer nearly as much as before. Still, the company continues to build a strong investment case with two approvals in hand, ano...